Pinpunya Riangrungroj

Pinpunya Riangrungroj

Auto-generated profile, based on publicly available information

Pinpunya Riangrungroj

National Science and Technology Development Agency (NSTDA), National Center for Genetic Engineering and Biotechnology (BIOTEC)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2023 in FEMS Microbiology Letters
Verified
Journal Article
Closed access
PDF file
PRPinpunya Riangrungroj
Pinpunya Riangrungroj
WVWonnop Visessanguan
Wonnop Visessanguan
ULUbolsree Leartsakulpanich
Ubolsree Leartsakulpanich
Bacterial ghosts (BGs) are non-viable empty bacterial cell envelopes with intact cellular morphology and native surface structure. BGs made from pathogenic bacteria are used for biomedical and pharmaceutical applications. However, incomplete pathogenic cell inactivation during BG preparation raises safety concerns that could limit the intended use. Therefore, safer bacterial cell types are needed for BG production. Here, we produced BGs from the food-grade Gram-positive bacterium Lactobacillus plantarum TBRC 2–4 by conditional expression of a prophage-encoded holin (LpHo). LpHo expression was regulated using the pheromone-inducible pSIP system and LpHo was localized to the cell membrane. Upon LpHo induction, a significant growth retardation and a drastic decrease in cell viability were observed. LpHo-induced cells also showed membrane pores by scanning electron microscopy, membrane depolarization by flow cytometry, and release of nucleic acid contents in the cell culture supernatant, consistent with the role of LpHo as a pore-forming protein and L. plantarum ghost formation. The holin-induced L. plantarum BG platform could be developed as a safer alternative vehicle for the delivery of biomolecules.

22 September 2022 in Experimental Parasitology
Verified
Journal Article
Closed access
BKBuabarn Kuaprasert
Buabarn Kuaprasert
PCPenchit Chitnumsub
Penchit Chitnumsub
ULUbolsree Leartsakulpanich
Ubolsree Leartsakulpanich
PRPinpunya Riangrungroj
Pinpunya Riangrungroj
WSWipa Suginta
Wipa Suginta
KCKiattawee Choowongkomon
Kiattawee Choowongkomon

5 June 2026 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
SSSuwitchaya Sirimanakul
Suwitchaya Sirimanakul
JHJoseph D. Hurley
Joseph D. Hurley
NVNakarin Vutipow
Nakarin Vutipow
FLFabien Loison
Fabien Loison
AKAnongnard Kasorn
Anongnard Kasorn
DWDujduan Waraho-Zhmayev
Dujduan Waraho-Zhmayev
Heart failure (HF) is a major global health concern, particularly in low- and middle-income countries where it is often underdiagnosed. Prognostic testing plays a crucial role in guiding treatment and monitoring disease progression. In this study, we developed an electrochemical assay-based prognostic kit for HF detection targeting soluble suppression of tumorigenicity 2 (sST2). This biomarker offers superior prognostic value compared to traditional methods as it remains stable regardless of patient demographics, including age, sex, obesity, and renal status. To reduce production costs and complexity of the test kit, single-domain antibody fragments (nanobodies) were used in place of conventional antibodies, and an electrochemical platform was used instead of ELISA. We obtained 19 candidate nanobodies from screening a naïve, fully synthetic yeast-display nanobody (Nb) library, and four of these (Nb1, Nb2, Nb5, and Nb13) were prioritized for further study on the basis of high affinity and low polyreactivity. Of these, Nb2 and Nb5 enabled sensitive electrochemical detection of sST2 with limits of detection of 3.37 and 3.00 ng/mL, respectively, in PBS buffer. Further validation using patient serum samples with the Nb5-based platform achieved quantitative detection of sST2 across a predilution concentration range from 0.75 to 93.09 ng/mL, facilitated by sample dilution to mitigate matrix effects and surface saturation. Both nanobodies exhibited high target specificity, with no observed cross-reactivity to other HF biomarkers or serum components. This novel prognostic tool can be produced and performed at low cost, providing a new option for heart failure diagnosis and treatment planning, particularly in low- and middle-income countries, where cost is a major cause of underdiagnosis.